Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of December 2018. The Company, a Swiss biopharmaceutical firm, announced a strategic partnership on December 11, 2018, to advance its Tau Morphomer small molecules for the treatment of Alzheimer's disease and other neurodegenerative conditions.
Key Financial Metrics and Transaction Details
The filing details a License and Collaboration Agreement and a Convertible Note Agreement with Eli Lilly and Company ("Lilly"). Key financial terms include:
- Total Potential Payments: Up to approximately CHF 1.9 billion (excluding royalties).
- Upfront Payment: CHF 80 million in cash from Lilly.
- Convertible Note: $50 million purchase price for a senior unsecured convertible note.
- Milestone Payments: Aggregate development, regulatory, and commercial milestones totaling up to CHF 1.7 billion.
- Royalties: Tiered royalties on net sales of licensed products at low double-digit percentages.
- Note Terms: 0.75% annual interest rate; automatic conversion into common shares at $13.83 per share on the 90th day after the agreement's effective date.
The filing text does not provide specific values for the Company's historical revenue, profit, cash flow, margins, or existing debt levels outside of this new transaction.
Material Changes and Operational Impact
This agreement represents a material change in the Company's business strategy and capital structure. Under the terms:
- AC Immune will conduct initial Phase 1 development of Tau small molecules, with certain costs reimbursable by Lilly.
- Lilly will fund and lead further clinical development and hold global commercialization rights for Alzheimer's disease.
- AC Immune retains development rights for orphan indications and holds co-development/co-promotion options for indications outside Alzheimer's disease.
Guidance, Risks, and Contingencies
Contingencies: The effectiveness of the License Agreement and any payments are conditioned upon customary antitrust review and the receipt of HSR (Hart-Scott-Rodino) clearance.
Termination Rights: Lilly may terminate the License Agreement with three months' written notice, subject to the agreement's terms.
Management Commentary: The filing does not include specific forward-looking guidance on financial performance beyond the potential payments outlined in the agreement.
Investor Verification Checklist
- Verify the receipt of HSR clearance and the effective date of the License Agreement.
- Confirm the timing of the $50 million convertible note conversion into common shares.
- Monitor the receipt of the CHF 80 million upfront payment and its impact on liquidity.
- Review the specific criteria for the CHF 1.7 billion in milestone payments to assess probability of realization.
- Check for any subsequent filings regarding the dilution impact of the convertible note conversion.